Yi Zhang

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Signaling Pathway

Inflammatory Response

Top Venues

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Li-Shan Yan, Shuang Cui, Brian Chi-Yan Cheng, Xing-Bin Yin, Yi-Wei Wang, Xin-Yu Qiu, Ci-Ren Nima, Yi Zhang, Shuo-Feng Zhang
Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug design, development and therapy 17 (2023)
Li-Shan Yan, Shuang Cui, Brian Chi-Yan Cheng, Xing-Bin Yin, Yi-Wei Wang, Xin-Yu Qiu, Ci-Ren Nima, Yi Zhang, Shuo-Feng Zhang
Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug design, development and therapy 17 (2023)
Li-Shan Yan, Shuang Cui, Brian Chi-Yan Cheng, Xing-Bin Yin, Yi-Wei Wang, Xin-Yu Qiu, Ci-Ren Nima, Yi Zhang, Shuo-Feng Zhang
Sichen Formula Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via Blocking the TLR4 Signaling Pathways. Drug design, development and therapy 17 (2023)
Yi Zhang, Brian Chi-Yan Cheng, Cui Li, Yonghua Tao, Chanjuan Yu, Xinyue Liu, Xiaoyan Gao, Gan Luo
Characterization and comparison of Re-Du-Ning aerosol particles generated by different jet nebulizers. RSC advances 9 (52) (2019)
Gan Luo, Jing Kong, Brian Chi-Yan Cheng, Hui Zhao, Xiu-Qiong Fu, Li-Shan Yan, Yu Ding, Yan-Ling Liu, Si-Yuan Pan, Shuo-Feng Zhang, Yi Zhang
Xiao Qing Long Tang essential oil exhibits inhibitory effects on the release of pro-inflammatory mediators by suppressing NF-κB, AP-1, and IRF3 signalling in the lipopolysaccharide-stimulated RAW264.7 cells. RSC advances 9 (23) (2019)